Home / Market News / $RHHBY
benzinga Corporate Catalyst Impact 75/100 ● positive

FDA Accepts Roche's Fenebrutinib NDA Under Priority Review For Relapsing And Primary Progressive MS, Backed By Phase III Data Showing 51.1%, 58.5% Relapse Reductions Vs Teriflunomide

Sep 30, 2026, 6:43 AM UTC · Primary ticker $RHHBY

Roche's fenebrutinib, an investigational BTK inhibitor, has received priority review from the FDA for relapsing and primary progressive multiple sclerosis (MS). This filing highlights strong Phase III data showing significant relapse reductions and a positive trend in delaying disability, positioning it as a potential first-in-class oral treatment for both forms of MS.

Roche announced that the FDA has accepted its New Drug Application (NDA) for fenebrutinib for priority review in relapsing and primary progressive multiple sclerosis (MS). This is a significant development as fenebrutinib demonstrated strong efficacy in Phase III trials, showing substantial reductions in relapses and a positive trend in delaying disability progression, even numerically outperforming Ocrevus in PPMS. If approved, fenebrutinib would be the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, potentially disrupting the existing MS treatment landscape. This creates a significant opportunity for Roche to capture market share in a large patient population, while posing a competitive threat to companies with established MS drugs. Short-term, this news is positive for Roche, while long-term implications depend on the final approval and market adoption. Traders should watch for further FDA updates and potential impacts on competitors' stock prices.

$RHHBY positive FDA priority review acceptance
$BIIB negative Increased competition for MS treatments
$NVS negative Increased competition for MS treatments
$BMY negative Increased competition for MS treatments
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.